All Articles
Oncology Experts Join Together to Provide Best Possible Care for Adolescents and Young Adults with Cancer
The Hematology/Oncology Pharmacy Association (HOPA) has partnered with Stupid Cancer, the leader in young adult cancer advocacy, research, and support, to develop tools for healthcare providers who serve the adolescent and young adult (AYA) patient commun

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (M

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Olutasidenib, with or without azacitidine, was well tolerated and showed meaningful clinical activity in patients with IDH1-mutated acute myeloid leukaemia.